Shilpa Pharma Lifesciences Limited

Unit-1: Plot No. 1A & 1A 'P', 1B, 2, 2A, 2B, 3A to 3E, 4A, 5A, 4B & 5B, Deosugur Industrial Area, Deosugur-584 170, Raichur District, Karnataka State, India.

CIN: U24100KA2020PLC134081

		CERTIFICATE OF	ANALYSIS		
	of the Material : TEMOZOLOMID				
	nercial Batch No.: Will be assigned a	fter approval			
Produ	etion Batch No. : TPM2220019		Drug License No.: KTK/25/256/89		
Batch quantity : 20.52 Kg			Dispatch Quantity: 240 g		
Mfg. I	Date : MAR-2022		Approved on : 26.03.2022		
Retest	Date : FEB-2025		Ref. A.R No. : 40000067435		
S.No.	Tests	Results	Specifications		
01.	Appearance Ph.Eur.1.4	Slightly pink powder	White or slightly brown or slightly pink powder.		
02.	Solubility Ph.Eur.1.4	Confirms	Slightly soluble in water, soluble in dimethyl sulfoxic very slightly soluble in ethanol(96 percent) ar practically insoluble in toluene.		
03.	Identification				
	By FTIR Ph.Eur.2.2.24	Confirms	The Infrared absorption spectrum of the Temozolomid should concordant with the spectrum obtained from Temozolomide standard.		
	By HPLC <i>Ph.Eur</i> .2.2.29 Confirms		The principal peak in the chromatogram obtained with the test solution (b) is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (d) in the assay.		
	By XRD In-house	Confirms	The X-ray diffractogram of the sample should confirm with polymorph form 1A.		
04.	Related Substances By HPLC Ph.Ei	ır.2.2.29			
	 Impurity-A(Sum of the peaks) 	Not detected	Not more than 0.15% w/w		
1	Impurity-B	Not detected	Not more than 0.15% w/w		
	Impurity-D	Not detected	Not more than 0.10% w/w		
	 Impurity-E 	Not detected	Not more than 0.10% w/w		
	 Each unspecified impurity 	Not detected	Not more than 0.10% w/w		
	Total impurities	Not detected	Not more than 0.5% w/w		
05.	Water content Ph.Eur.2.5.32	0.10%	Not more than 0.4% w/w		
06.	Sulphated Ash Ph.Eur.2.4.14	0.05%	Not more than 0.1% w/w		
07.	Assay By HPLC On anhydrous substances <i>Ph.Eur.2.2.29</i>	99.8% light and moisture.	Between 98.0% w/w to 102.0% w/w		

Page 01 of 02

Prepared by	Checked by	Approved by
D.Lokeswara Rao	Rajendra S.Nikam	O.Maheswara Reddy
Sr.Executive-QC	Asst Manager-QC	Dy.Manager-QA
D. M 06/09/22	19/206/09/22	00009 22
	D.Lokeswara Rao	D.Lokeswara Rao Rajendra S.Nikam

Shilpa Pharma Lifesciences Limited

Unit-1: Plot No. 1A & 1A 'P', 1B, 2, 2A, 2B, 3A to 3E, 4A, 5A, 4B & 5B, Deosugur Industrial Area, Deosugur-584 170, Raichur District, Karnataka State, India.

CIN: U24100KA2020PLC134081

Name	of the Material : TEMOZOLOMIDE	EP		
Comm	nercial Batch No.: Will be assigned after	er approval		
Production Batch No.: TPM2220019			Drug License No.: KTK/25/256/89	
Batch quantity : 20.52 Kg			Dispatch Quantity: 240 g	
Mfg. Date : MAR-2022			Approved on : 26.03.2022	
Retest	Date : FEB-2025		Ref. A.R No. : 40000067435	
S.No.	Tests	Results	Specifications	
08.	Residual Solvents By GC In-house			
	 Acetonitrile 	Below LOQ	Not more than 150 ppm (LOQ: 35 ppm)	
	Ethyl acetate	Not detected	Not more than 1000 ppm (LOQ: 31 ppm)	
	Acetone	Below LOQ	Not more than 2000 ppm (LOQ: 40 ppm)	
	 Total residual solvents 	Below LOQ	Not more than 2000 ppm	
09.	Microbial Enumeration tests			
	A)Total viable aerobic count <i>Ph.Eur.</i> 2.6.12			
	 Total aerobic microbial count 	Less than 10 cfu/g	Not more than 1000 cfu/g	
	 Total yeasts and molds count 	Less than 10 cfu/g	Not more than 100 cfu/g	
	B) Specified Microorganisms Ph.Eur.2.6.13			
	 Escherichia coli 	Absent	Should be absent	
	 Pseudomonas aeruginosa 	Absent	Should be absent	
	 Staphylococcus aureus 	Absent	Should be absent	
	 Salmonella 	Absent	Should be absent	
	 Bile-Tolerant Gram negative Bacteria 	Absent	Should be absent	
	 Clostridia 	Absent	Should be absent	
	 Candida albicans 	Absent	Should be absent	

Page 02 of 02

	Prepared by	Checked by	Approved by
Name	D.Lokeswara Rao	Rajendra S.Nikam	O.Maheswara Reddy
Designation	Sr.Executive-QC	Asst Manager-QC	Dy.Manager-QA
Sign & Date	D. M06/09/22	192 6 0 9 122	06/09/22